Effect of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: A double blind, randomized, controlled trial


      Background & aims

      The aim of this study was to investigate whether the consumption of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 (5×107cfu/tablet) during at least 3 months influences the severity of symptoms and the incidence and duration of the common cold.


      A randomized, double-blind, placebo-controlled intervention study was performed over at least 3 months during two winter/spring periods. Four hundred and seventy nine healthy adults (aged 18–67) were supplemented daily with vitamins and minerals with or without the probiotic bacteria. Cellular immune parameters were evaluated in a randomly drawn subgroup of 122 volunteers before and after 14 days of supplementation. During common cold episodes, the participants recorded symptoms daily. Stool samples were collected before and after 14 days of probiotic supplementation to quantify fecal Lactobacilli and Bifidobacteria using qRT-PCR.


      The total symptom score, the duration of common cold episodes, and days with fever during an episode were lower in the probiotic-treated group than in the control group: 79.3±7.4 vs. 102.5±12.2 points ( P = 0.056 ) , 7.0±0.5 vs. 8.9±1.0 days ( P = 0.045 ) , 0.24±0.1 vs. 1.0±0.3 days ( P = 0.017 ) . A significantly higher enhancement of cytotoxic plus T suppressor cells (CD8+) and a higher enhancement of T helper cells (CD4+) was observed in the probiotic-treated group. Fecal lactobacilli and bifidobacteria increased significantly after probiotic supplementation.


      The intake of probiotic bacteria during at least 3 months significantly shortened common cold episodes by almost 2 days and reduced the severity of symptoms.


      To read this article in full you will need to make a payment
      Subscribe to Clinical Nutrition
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Heikkinen T.
        • Järvinen A.
        The common cold.
        Lancet. 2003; 361: 51-59
        • Blum S.
        • Haller D.
        • Pfeifer A.
        • Schiffrin E.J.
        Probiotics and immune response.
        Clin Rev Allergy Immunol. 2002; 22: 287-309
        • Isolauri E.
        • Sutas Y.
        • Kankaanpaa P.
        • Arvilommi H.
        • Salminen S.
        Probiotics: effects on immunity.
        Am J Clin Nutr. 2001; 73: 444S-450S
        • Marteau P.R.
        • de Vrese M.
        • Cellier C.J.
        • Schrezenmeir J.
        Protection from gastrointestinal diseases with the use of probiotic bacteria.
        Am J Clin Nutr. 2001; 73: 430S-436S
        • de Vrese M.
        • Schrezenmeir J.
        Probiotics and non-intestinal infectious conditions.
        Br J Nutr. 2002; 88: 59-66
        • Yasui H.
        • Kiyosima J.
        • Hori T.
        • Shida K.
        Protection against influenza infection of mice fed Bifidobacterium breve YIT4064.
        Clin Diagn Lab Immunol. 1999; 6: 186-192
        • Lykova E.A.
        • Vorob’ev A.A.
        • Bokovoi A.G.
        • et al.
        Disruption of microbiocenosis of the large intestine and the immune and interferon status in children with bacterial complications of acute viral infections of the respiratory tract and their correction by high doses of bifidumbacterin forte.
        Antibiot Khimioter. 2000; 45 ([in Russian]): 22-27
        • Hatakka K.
        • Savilahti E.
        • Ponka A.
        • et al.
        Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial.
        Br Med J. 2001; 322: 1327-1329
        • Habermann W.
        • Zimmermann K.
        • Skarabis H.
        • Kunze R.
        • Rusch V.
        Influence of a bacterial immunostimulant (human Enterococcus faecalis bacterin) on the recurrence of relapses in patients with chronic bronchitis.
        Arzneimittelforschung. 2001; 51 ([in German]): 931-937
        • Habermann W.
        • Zimmermann K.
        • Skarabis H.
        • Kunze R.
        • Rusch V.
        Reduction of acute relapses in patients with chronic recurrent hypertrophic sinusitis during treatment with a bacterial immunostimulant (Enterococcus faecalis bacteria of human origin—a medical probiotic).
        Arzneimittelforschung. 2002; 52 ([in German]): 622-627
        • Turchet P.
        • Laurenzano M.
        • Auboiron S.
        • Antoine J.M.
        Effect of fermented milk containing the probiotic Lactobacillus casei DN-114001 on winter infections in free-living elderly subjects: a randomised, controlled pilot study.
        J Nutr Health Aging. 2003; 7: 75-77
        • Honma M.
        On effect of lactic acid bacteria: biological significance.
        New Med Clin. 1986; 35: 1-19
        • Stansfield S.K.
        • Pierre-Louis M.
        • Lerebours G.
        • Augustin A.
        Vitamin A supplementation and increased prevalence of childhood diarrhoea and acute respiratory infections.
        Lancet. 1993; 342: 578-582
        • Mossad S.
        • Macknin M.
        • Medendorp S.
        • Mason P.
        Zinc gluconate lozenges for treating the common cold: a randomised, double-blind, control-controlled study.
        Ann Intern Med. 1996; 125: 81-88
        • Lim L.C.L.
        • Fiordalisi M.N.
        • Mantell J.L.
        • Schmitz J.L.
        • Folds J.D.
        A whole-blood assay for qualitative and semiquantitative measurements of CD69 surface expression on CD4 and CD8 T lymphocytes using flow cytometry.
        Clin Diagn Lab Immunol. 1998; 3: 392-398
        • Hirt W.
        • Nebe T.
        • Birr C.
        Phagotest and bursttest (Phagoburst), test kits for study of phagocyte functions.
        Wien Klin Wochenschr. 1994; 106 ([in German]): 250-252
        • Walter J.
        • Hertel C.
        • Tannock G.W.
        • Lis C.M.
        • Munro K.
        • Hammes W.P.
        Detection of Lactobacillus, Pediococcus, Leuconostoc, and Weissella species in human feces by using group-specific PCR primers and denaturing gradient gel electrophoresis.
        Appl Environ Microbiol. 2001; 67: 2578-2585
        • Ott S.J.
        • Musfeldt M.
        • Ullmann U.
        • Hampe J.
        • Schreiber S.
        Quantification of intestinal bacterial populations by real-time PCR using a universal primer set and MGB probes: a global approach to the enteric flora.
        J Clin Microbiol. 2004; 42: 2566-2572
        • Langendijk P.S.
        • Schut F.
        • Jansen G.J.
        • et al.
        Quantitative fluorescence in situ hybridization of Bifidobacterium spp. with genus-specific 16S rRNA-targeted probes and its application in fecal samples.
        Appl Environ Microbiol. 1995; 61: 3069-3075
        • Bernhard A.E.
        • Field K.G.
        Identification of nonpoint sources of fecal pollution in coastal waters by using host-specific 16S ribosomal DNA genetic markers from fecal anaerobes.
        Appl Environ Microbiol. 2000; 66: 1587-1594
        • Treanor J.J.
        • Hayden F.G.
        • Vrooman P.S.
        • et al.
        Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.
        J Am Med Assoc. 2000; 283: 1016-1024
        • Hoheisel O.
        • Sandberg M.
        • Bertram S.
        • Bulitta M.
        • Schäfer M.
        Echinagard treatment shortens the course of the common cold: a double-blind, placebo-controlled clinical trial.
        Eur J Clin Res. 1997; 9: 261-268
        • MacIntyre S.
        • Pritchard C.
        Comparisons between the self-assessed and observer-assessed presence and severity of colds.
        Soc Sci Med. 1989; 29: 1243-1248
        • Hayden F.G.
        • Gubareva L.A.
        • Monto A.S.
        • et al.
        Inhaled Zanamivir for the prevention of influenza in families.
        N Engl J Med. 2000; 343: 1282-1289
        • Hessle C.
        • Hanson L.Å
        • Wold A.E.
        Lactobacilli from human gastrointestinal mucosa are strong stimulators of IL-12 production.
        Clin Exp Immunol. 1999; 116: 276-282
        • Borruel N.
        • Casellas F.
        • Antolín M.
        • et al.
        Effects of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa.
        Am J Gastroenterol. 2003; 98: 865-870
        • Christensen H.R.
        • Frokiaer H.
        • Pestka J.J.
        Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells.
        J Immunol. 2002; 168: 171-178
        • Cario E.
        • Podolsky D.K.
        Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease.
        Infect Immun. 2000; 68: 7010-7017
        • Muzio M.
        • Bosisio D.
        • Polentarutti N.
        • et al.
        Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells.
        J Immunol. 2000; 164: 5998-6004
        • Kitazawa H.
        • Ino T.
        • Kawai Y.
        • Itoh T.
        • Saito T.
        A novel immunostimulating aspect of Lactobacillus gasseri: induction of “Gasserokine” as chemoattractants for macrophages.
        Int J Food Microbiol. 2002; 77: 29-38
        • Chandra R.K.
        Effect of vitamin and trace-element supplementation on immune responses and infections in elderly subjects.
        Lancet. 1992; 340: 1124-1127
        • Schrezenmeir J.
        • de Vrese M.
        Probiotics, prebiotics, and synbiotics—approaching a definition.
        Am J Clin Nutr. 2001; 73: 361S-364S